Hyperthermic Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial-Reference-Cited by-同舟云学术

Hyperthermic Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

Published:2023-02 Issue:1 Volume:6 Page:58-66
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Angulo Javier C.,Álvarez-Ossorio José L.,Domínguez-Escrig José L.,Moyano José L.,Sousa Alejandro,Fernández Jesús M.,Gómez-Veiga Francisco,Unda Miguel,Carballido Joaquín,Carrero Victor,Fernandez-Aparicio Tomás,García de Jalón Ángel,Solsona Eduardo,Inman Brant,Palou Joan

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

3. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group;Brausi;J Urol,2011

4. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer;Kamat;J Urol,2014

5. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ);Babjuk;Eur Urol,2022

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered;World Journal of Urology;2024-09-11

2. Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review;Urologic Oncology: Seminars and Original Investigations;2024-09

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

4. Mitomycin C vs. Bacillus Calmette–Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients—A comparative analysis from a single center;Urologic Oncology: Seminars and Original Investigations;2024-07

5. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer;European Urology Oncology;2024-06